Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes

American Journal of Medicine

Volumn 126, Issue 9 SUPPL.1, 2013, Pages

  Ross, Stuart A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Clinical inertia; Glycemic control; Nonadherence

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA;

ALBUMINURIA; ANXIETY; ARTICLE; BONE DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETIC RETINOPATHY; DIARRHEA; DRUG DOSE INTENSIFICATION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; HYPOGLYCEMIA; INJECTION PAIN; NAUSEA; NEEDLE; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

CLINICAL INERTIA; GLYCEMIC CONTROL; NONADHERENCE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIARRHEA; FEAR; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS; MEDICATION ADHERENCE; NAUSEA; PATIENT CARE PLANNING; PATIENT EDUCATION AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIAN-PATIENT RELATIONS; WEIGHT GAIN;

EID: 84882282813     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2013.06.012     Document Type: Article

References (99)

1. K.K. Ray, S.R.K. Seshasai, and S. Wijesuriya Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Lancet 373 2009 1765 1772
2. ADVANCE Collaborative Group A. Patel, S. MacMahon, and J. Chalmers Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572 (Pubitemid 351831357)
3. J. Berger Economic and clinical impact of innovative pharmacy benefit designs in the management of diabetes pharmacotherapy Am J Manag Care 13 Suppl 2 2007 S55 S58
4. T.J. Hoerger, J.E. Segel, E.W. Gregg, and J.B. Saadine Is glycemic control improving in US adults? Diabetes Care 31 2008 81 86
5. M. Braga, A. Casanova, and H. Teoh Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada Can J Cardiol 26 2010 297 302
6. S.E. Inzucchi, R.M. Bergenstal, and J.B. Buse Position statement: management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 55 2012 1577 1596
7. T. Bailey Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm Am J Med 126 Suppl 2013 S10 S20
8. B.A. Briesacher, S.E. Andrade, H. Fouayzi, and K.A. Chan Comparison of drug adherence rates among patients with seven different medical conditions Pharmacotherapy 28 2008 437 443 (Pubitemid 351466455)
9. A.J. Karter, U. Subramanian, and C. Saha Barriers to insulin initiation: the translating research into action for diabetes insulin starts project Diabetes Care 33 2010 733 735
10. S.B. Harris, J. Kapor, C.N. Lank, A.R. Willan, and T. Houston Clinical inertia in patients with T2DM requiring insulin in family practice Can Fam Physician 56 2010 e418 e424
11. A. Zafar, M. Davies, A. Azhar, and K. Khunti Clinical inertia in management of T2DM Prim Care Diabetes 4 2010 203 207
12. J.D. Allen, F.R. Curtiss, and K.A. Fairman Nonadherence, clinical inertia, or therapeutic inertia? J Manag Care Pharm 15 2009 690 695
13. S. Kripalani, F. LeFevre, and C.O. Phillips Deficits in communication and information transfer between hospital-based and primary care physicians: implications for patient safety and continuity of care JAMA 297 2007 831 841 (Pubitemid 46333948)
14. J.L. Green, J.N. Hawley, and K.J. Rask Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharmacother 5 2007 31 39 (Pubitemid 47099502)
15. New England Healthcare Institute. Thinking outside the pillbox: a system-wide approach to improving patient medication adherence in chronic disease. August 12, 2009. Available at: http://www.nehi.net/publications/44/ thinking-outside-the-pillbox-a-systemwide-approach-to-improving-patient- medication-adherence-for-chronic-disease. Accessed May 9, 2013.
16. D. Tripathy, and A.O. Chavez Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus Curr Diab Rep 10 2010 184 191
17. I.M. Stratton, A.I. Adler, and H.A. Neil Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 2000 405 412 (Pubitemid 30609442)
18. R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, and H.A. Neil 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 2008 1577 1589
19. R.A. DeFronzo From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 2009 773 795
20. R.E. Pratley The early treatment of type 2 diabetes Am J Med 126 Suppl 2013 S2 S9
21. American Diabetes Association Standards of medical care in diabetes - 2012 Diabetes Care 35 Suppl 1 2012 S11 S63
22. Canadian Diabetes Association Clinical practice guidelines for the prevention and management of diabetes in Canada Can J Diabetes 234 Suppl 1 2008 S1 S101
23. Y. Handelsman, L. Blonde, and Z.T. Bloomgarden American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan Endocr Pract 17 Suppl 2 2011 S1 S53
24. A.J. Garber, M.J. Abrahamson, and J.I. Barzilay AACE comprehensive diabetes management algorithm 2013 Endocr Pract 19 2013 327 336
25. S.A. Amiel, T. Dixon, R. Mann, and K. Jameson Hypoglycaemia in type 2 diabetes Diabet Med 25 2008 245 254 (Pubitemid 351322690)
26. P.E. Cryer, and B.P. Childs Negotiating the barrier of hypoglycemia in diabetes Diabetes Spectr 15 2002 20 27
27. K.B. Degn, B. Brock, and C.B. Juhl Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia Diabetes 53 2004 2397 2403 (Pubitemid 39145595)
28. C.T. Kodl, and E.R. Seaquist Practical strategies to normalize hyperglycemia without undue hypoglycemia in type 2 diabetes mellitus Curr Diab Rep 8 2008 375 382
29. P.E. Cryer The barrier of hypoglycemia in diabetes Diabetes 57 2008 3169 3176
30. M. Korytkowski When oral agents fail: practical barriers to starting insulin Int J Obes 26 Suppl 3 2002 S18 S24
31. P.E. Clark, C.R. Okenfuss, and M. Campbell Half-unit dose accuracy with HumaPen® Luxura™ HD: an insulin pen for patients who need precise dosing Diabetes Sci Technol 4 2010 353 356
32. J. Rosenstock, G. Dailey, and M. Massi-Benedetti Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes Diabetes Care 28 2005 950 955 (Pubitemid 40434505)
33. A. Philis-Tsimikas, G. Charpentier, and P. Clauson Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes Clin Ther 28 2006 1569 1581 (Pubitemid 44856694)
34. R.R. Holman, A.J. Farmer, and M.J. Davies Three-year efficacy of complex insulin regimens in type 2 diabetes N Engl J Med 361 2009 1736 1747
35. H.E. Bays, R.H. Chapman, and S. Grandy The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys Int J Clin Pract 61 2007 737 747 (Pubitemid 46587875)
36. A.B. Hauber, A.F. Mohamed, F.R. Johnson, and H. Falvey Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents Diabet Med 26 2009 416 424
37. E. Marrett, T. Stargardt, P. Mavros, and C.M. Alexander Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain Diabetes Obes Metab 11 2009 1138 1144
38. D. Russell-Jones, and R. Khan Insulin-associated weight gain in diabetes - causes, effects and coping strategies Diabetes Obes Metab 9 2007 799 812 (Pubitemid 47555203)
39. J. Mitri, and O. Hamdy Diabetes medications and body weight Expert Opin Drug Saf 8 2009 573 584
40. O.J. Phung, J.M. Scholle, M. Talwar, and C.I. Coleman Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes JAMA 303 2010 1410 1418
41. K. Hermansen, and M. Davies Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 9 2007 209 217 (Pubitemid 46502039)
42. O. Hamdy, and C. Carver The why WAIT program: improving clinical outcomes through weight management in type 2 diabetes Curr Diab Rep 8 2008 413 420
43. O. Hamdy, A. Goebel-Fabbri, and C. Carver The Why WAIT program: a novel model for diabetes weight management in routine clinical practice Obes Manage J 4 2008 176 183
44. B.W. Bode, M.A. Testa, M. Magwire LEAD-3 Study Group Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes Diabetes Obes Metab 12 2010 604 612
45. J.H. Best, K.S. Boye, and R.R. Rubin Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily Diabet Med 26 2009 722 728
46. Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride) product label. 2008. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/label/2008/020357s031,021202s016lbl.pdf. Accessed May 9, 2013.
47. Novo Nordisk A/S. Victoza® (liraglutide) prescribing information. 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 022341s004lbl.pdf. Accessed May 9, 2013.
48. Amylin Pharmaceuticals, Inc. Byetta® (exenatide) prescribing information. 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2011/021773s029s030lbl.pdf. Accessed May 9, 2013.
49. Eli Lilly and Company Ltd. Bydureon® (exenatide extended release) prescribing information. 2012. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/022200s000lbl.pdf. Accessed May 9, 2013.
50. J.B. Buse, J. Rosenstock, G. Sesti LEAD-6 study group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 2009 39 47
51. J.B. Buse, M.A. Nauck, and T. Forst Efficacy and safety of exenatide once-weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study Diabetologia 54 Suppl 1 2011 S38
52. J. Unger, and C.G. Parkin Glucagon-like peptide-1 (GLP-1) receptor agonists: differentiating the new medications Diabetes Ther 2 2011 29 39
53. M. Peyrot, R.R. Rubin, and T. Lauritzen Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study Diabet Med 22 2005 1379 1385 (Pubitemid 41391315)
54. A.Z. Fu, Y. Qiu, and L. Radican Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes Curr Med Res Opin 25 2009 1413 1420
55. M. Peyrot, R.R. Rubin, D.F. Kruger, and L.B. Travis Correlates of insulin injection omission Diabetes Care 33 2010 240 245
56. R.R. Rubin, M. Peyrot, D.F. Kruger, and L.B. Travis Barriers to insulin injection therapy: patient and health care provider perspectives Diabetes Educ 35 2009 1014 1022
57. E.D. Mollema, F.J. Snoek, R.J. Heine, and H.M. van der Ploeg Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening Diabet Med 18 2001 671 674 (Pubitemid 32823067)
58. L. Arendt-Nielsen, H. Egekvist, and P. Bjerring Pain following controlled cutaneous insertion of needles with different diameters Somatosens Mot Res 23 2006 37 43 (Pubitemid 44114991)
59. V. Hutchins, B. Zhang, R.L. Fleurence, G. Krishnarajah, and J. Graham A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes Curr Med Res Opin 27 2011 1157 1168
60. S. Levit, Y. Toledano, and J. Wainstein Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes Int J Clin Pract 65 2011 165 171
61. J.M. Tibaldi Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes Clin Ther 33 2011 1630 1642
62. Eli Lilly and Company Ltd. Bydureon® patient information. 2011. Available at: http://www.medicines.org.uk/EMC/medicine/24669/PIL/ Bydureon+2mg+powder+and+solvent+for+prolonged- release+suspension+for+injection%2c+User+manual/. Accessed May 9, 2013.
63. S. Heller, A.M.O. Francisco, H. Pei, and D. Russell-Jones Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in type 1 diabetes Diabetes 60 Suppl 1 2011 A19 [abstract 70-OR]
64. L. Meneghini, S.L. Atkin, and S. Bain Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once-daily at the same time each day in people with type 2 diabetes Diabetes 60 Suppl 1 2011 35-LB [abstract 35-LB]
65. D. Cobden, W.C. Lee, S. Balu, A.V. Joshi, and C.L. Pashos Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus Pharmacotherapy 27 2007 948 962 (Pubitemid 46986681)
66. M. Korytkowski, D. Bell, C. Jacobsen, and R. Suwannasari A multi-centre, randomized, open-label, comparative, two-period crossover trial of preference, efficacy and safety profiles of a pre-filled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or type 2 diabetes mellitus Clin Ther 25 2003 2836 2848 (Pubitemid 37510593)
67. T.L. Pearson Practical aspects of insulin pen devices J Diab Sci Technol 4 2010 522 531
68. C. Asche, L. Shane-McWhorter, and S. Raparla Health economics and compliance of vials/syringes versus pen devices: a review of the evidence Diabetes Technol Ther Suppl 1 2010 S101 S108
69. M. Peyrot, and R.R. Rubin Physician perception and recommendation of insulin pens for patients with type 2 diabetes mellitus Curr Med Res Opin 24 2008 2413 2422
70. E.S. Kimbal Coverage of insulin delivery devices and basal insulin analogs by US managed care organizations J Med Econ 14 2011 720 728
71. T. Bodenheimer, K. Lorig, H. Holman, and K. Grumbach Patient self-management of chronic disease in primary care JAMA 288 2002 2469 2475 (Pubitemid 35340544)
72. S.D. McMurray, G. Johnson, S. Davis, and K. McDougall Diabetes education and care management significantly improve patient outcomes in the dialysis unit Am J Kidney Dis 40 2002 566 575 (Pubitemid 34971286)
73. T.L. Gary, J.M. Genkinger, E. Guallar, M. Peyrot, and F.L. Brancati Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes Diabetes Educ 29 2003 488 501 (Pubitemid 44858394)
74. T. Deakin, C.E. McShane, J.E. Cade, and R.D. Williams Group based training for self-management strategies in people with type 2 diabetes mellitus Cochrane Database Syst Rev 2 2005 CD003417
75. M.M. Funnell, T.L. Brown, and B.P. Childs National standards for diabetes self-management education Diabetes Care 35 Suppl 1 2012 S101 S108
76. H.D. Tildesley, A.B. Mazanderani, and S.A. Ross Effect of internet therapeutic intervention on A1C levels in patients with type 2 diabetes treated with insulin Diabetes Care 33 2010 1738 1740
77. M. Boaz, K. Hellman, and J. Wainstein An automated telemedicine system improved patient-reported well-being Diabetes Technol Ther 11 2009 181 186
78. E. Russell-Minda, J. Jutai, and M. Speechley Health technologies for monitoring and managing diabetes: a systematic review J Diabetes Sci Technol 3 2009 1460 1471
79. A.C. Tricco, N.M. Ivers, and J.M. Grimshaw Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis Lancet 379 2012 2252 2261
80. L.S. Phillips, W.T. Branch, and C.B. Cook Clinical inertia Ann Intern Med 135 2001 825 834 (Pubitemid 33051266)
81. I.M. el-Kebbi, D.C. Ziemer, and V.C. Musey Diabetes in urban African-Americans. IX. Provider adherence to management protocols Diabetes Care 20 1997 698 703 (Pubitemid 27202515)
82. S.B. Harris, J.M. Ekoé, Y. Zdanowicz, and S. Webster-Bogaert Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study) Diabetes Res Clin Pract 70 2005 90 97 (Pubitemid 41207652)
83. R. Grant, A.S. Adams, and C.M. Trinacty Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management Diabetes Care 30 2007 807 812 (Pubitemid 46556571)
84. S.A. Ross, J.-F. Yale, J. Hahn, and J.R. Conway Baseline data from SOLVE imply initiation of insulin therapy remains delayed for many patients in Canadian primary care of type 2 diabetes Diabetes 59 Suppl 1 2010 A600 [abstract 2290-PO]
85. C.F. Schaefer Clinical Inertia: overcoming a major barrier to diabetes management Insulin 1 2006 61 64
86. M. Davies, R. Pratley, M. Hammer, A.B. Thomsen, and R. Cuddihy Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metformin Diabet Med 28 2010 333 337
87. R. Houlden, S. Ross, and S. Harris Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of type 2 diabetes: The Canadian INSIGHT Study Diabetes Res Clin Pract 78 2007 254 258 (Pubitemid 47451531)
88. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group H.C. Gerstein, M.E. Miller, and R.P. Byington Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559 (Pubitemid 351831356)
89. M.C. Riddle Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial Circulation 122 2010 844 846
90. M.C. Riddle Counterpoint: intensive glucose control and mortality in ACCORD - still looking for clues Diabetes Care 33 2010 2722 2724
91. J.M. Lachin Point: intensive glycemic control and mortality in ACCORD - a chance finding? Diabetes Care 33 2010 2719 2721
92. M.C. Riddle, W.T. Ambrosius, D.J. Brillon Action to Control Cardiovascular Risk in Diabetes Investigators Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial Diabetes Care 33 2010 983 990
93. D.E. Bonds, M.E. Miller, and R.M. Bergenstal The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study BMJ 340 2010 b4909
94. F. Ismail-Beigi, T. Craven, and M.A. Banerji Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial Lancet 376 2010 419 430
95. W. Duckworth, C. Abraira, and T. Moritz Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2009 129 139
96. K.L. Cavanaugh Diabetes management issues for patients with chronic kidney disease Clin Diabetes 25 2007 90 97 (Pubitemid 47173894)
97. Boehringer Ingelheim Pharmaceuticals, Inc. Tradjenta® (linagliptin) product label. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2011/201280lbl.pdf. Accessed September 25, 2012.
98. Bristol-Myers Squibb. Onglyza® (saxagliptin) product label. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/022350lbl.pdf. Accessed May 9, 2013.
99. Merck & Co., Inc. JANUVIA™ (sitagliptin) product label. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/ 021995lbl.pdf. Accessed May 9, 2013.